| Literature DB >> 27040498 |
Romain Banchereau1, Seunghee Hong1, Brandi Cantarel1, Nicole Baldwin1, Jeanine Baisch1, Michelle Edens1, Alma-Martina Cepika1, Peter Acs1, Jacob Turner1, Esperanza Anguiano1, Parvathi Vinod1, Shaheen Kahn2, Gerlinde Obermoser1, Derek Blankenship1, Edward Wakeland2, Lorien Nassi3, Alisa Gotte4, Marilynn Punaro3, Yong-Jun Liu5, Jacques Banchereau6, Jose Rossello-Urgell1, Tracey Wright3, Virginia Pascual7.
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by loss of tolerance to nucleic acids and highly diverse clinical manifestations. To assess its molecular heterogeneity, we longitudinally profiled the blood transcriptome of 158 pediatric patients. Using mixed models accounting for repeated measurements, demographics, treatment, disease activity (DA), and nephritis class, we confirmed a prevalent IFN signature and identified a plasmablast signature as the most robust biomarker of DA. We detected gradual enrichment of neutrophil transcripts during progression to active nephritis and distinct signatures in response to treatment in different nephritis subclasses. Importantly, personalized immunomonitoring uncovered individual correlates of disease activity that enabled patient stratification into seven groups, supported by patient genotypes. Our study uncovers the molecular heterogeneity of SLE and provides an explanation for the failure of clinical trials. This approach may improve trial design and implementation of tailored therapies in genetically and clinically complex autoimmune diseases. PAPERCLIP.Entities:
Mesh:
Year: 2016 PMID: 27040498 PMCID: PMC5426482 DOI: 10.1016/j.cell.2016.03.008
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582